1. In Vivo
  2. >>Deal-Making

Device/Diagnostics Quarterly Deal-Making Statistics, Q3 2017

A look at the financing, M&A and alliance activity July–September 2017

 
• By Amanda Micklus and Maureen Riordan

Third-quarter device financing at $2.38 billion – almost half of that amount from CooperSurgical's $1.1 billion bridge loan – was double the Q2 total, while device acquisitions showed a steep decrease at $3.38 billion versus Q2's $33.4 billion. Diagnostics fundraising also was up in the third quarter, reaching $2.4 billion (a 133% increase over Q2) mostly from Thermo Fisher Scientific's $1.5 billion follow-on offering, which accounted for 63% of the total. In line with the previous quarter's $1.7 billion in M&A, Q3 diagnostics acquisitions had an aggregate value of $1.8 billion, led by Konica Minolta's $1 billion buy of Ambry Genetics.

Quarterly Stats_1200x675

Financing by device companies in the third quarter of 2017 totaled $2.38 billion, double Q2's $1.2 billion. (See Exhibit 1.) Debt again this quarter made up most of the aggregate financing dollars (accounting for 61% of the total this time), but almost half of that category's amount came from outlier CooperSurgical Inc.(the gynecological devices division of Cooper Cos. Inc.), which entered a $1.1 billion bridge loan [See Deal] to fund its acquisition (of the same amount) of the Paragard intrauterine device (IUD) from Teva Pharmaceutical Industries Ltd.[See Deal] (Also see "Teva's US IUD Brings In $1.1bn For The Embattled Generics Firm" - Scrip, 12 September, 2017.)

Open Media

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.